Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A

The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.

Inclusion Criteria:

• Age 16 or over.
• Have documentation of physician-confirmed diagnosis of moderate or severe Hemophilia A (severity defined as moderate = FVIII activity 1% to 5% and severe = FVIII activity ≤1%).
• Signed written informed consent provided by the patient or the patient's parents for patients under the age of 18 (dependent of local regulations).
• Signed written assent is also required for patients under the age 18 years (dependent on local regulations).
• Plan to receive at least half of their Hemophilia care at the registry site.
• Willing and able to enter data as per the data collection schedule.
• Currently receiving prophylactic or on demand treatment (including within last 6months for on demand).
• Expected life expectancy of at least 2 years.

Exclusion Criteria:

• Patients with Hemophilia B
• Patients with von Willebrand disease (vWD)
• Patients with other rare bleeding disorders
• Unable to comply with the study protocol